Interestingly, Herbid et al. showed in a previous study that the adjustment of clinical doses according to CYP2D6 and CYP2C19 polymorphisms resulted in a reduction of treatment costs in schizophrenia patients showing poor or ultra-rapid metabolism33. The gene discussed is CYP2C19; the disease is schizophrenia.